Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Profit After Tax (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Profit After Tax for 9 consecutive years, with -$46.8 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 35.45% to -$46.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$191.1 million through Dec 2025, up 15.99% year-over-year, with the annual reading at -$191.1 million for FY2025, 15.99% up from the prior year.
  • Profit After Tax hit -$46.8 million in Q4 2025 for Sutro Biopharma, up from -$56.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $31.1 million in Q4 2023 to a low of -$76.0 million in Q1 2025.
  • Historically, Profit After Tax has averaged -$37.5 million across 5 years, with a median of -$38.8 million in 2022.
  • Biggest five-year swings in Profit After Tax: soared 189.8% in 2023 and later crashed 333.2% in 2024.
  • Year by year, Profit After Tax stood at -$38.1 million in 2021, then rose by 9.26% to -$34.6 million in 2022, then skyrocketed by 189.8% to $31.1 million in 2023, then plummeted by 333.2% to -$72.4 million in 2024, then surged by 35.45% to -$46.8 million in 2025.
  • Business Quant data shows Profit After Tax for STRO at -$46.8 million in Q4 2025, -$56.9 million in Q3 2025, and -$11.5 million in Q2 2025.